19191 - Ph3 Nivo +/- Doce mPC 7DX
A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)
Disease Types: Prostate,&nbs
Available at: {clinical_trial_location backspace="7"}19191 - Ph3 Nivo +/- Doce mPC 7DX, {/clinical_trial_location}
Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}
{clinical_trial_description}